ESLICARBAZEPINE ACETATE - Generic Drug Details

What are the generic drug sources for eslicarbazepine acetate and what is the scope of patent protection?

Eslicarbazepine acetate is the generic ingredient in two branded drugs marketed by Sumitomo Pharma Am, Alkem Labs Ltd, Apotex, Dr Reddys, Hetero Labs Ltd V, Jubilant Generics, Lupin Ltd, Sph Zhongxi Pharm, and Torrent, and is included in nine NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eslicarbazepine acetate has ninety-three patent family members in twenty-six countries.

There are twelve drug master file entries for eslicarbazepine acetate. Eight suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for ESLICARBAZEPINE ACETATE

International Patents:	93
US Patents:	7
Tradenames:	2
Applicants:	9
NDAs:	9
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	52
Patent Applications:	721
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ESLICARBAZEPINE ACETATE
What excipients (inactive ingredients) are in ESLICARBAZEPINE ACETATE?	ESLICARBAZEPINE ACETATE excipients list
DailyMed Link:	ESLICARBAZEPINE ACETATE at DailyMed

Recent Clinical Trials for ESLICARBAZEPINE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Whanin Pharmaceutical Company	Phase 1
Bial - Portela C S.A.	PHASE2
Stanford University	Phase 4

See all ESLICARBAZEPINE ACETATE clinical trials

Generic filers with tentative approvals for ESLICARBAZEPINE ACETATE

Applicant	Application No.	Strength	Dosage Form
		600MG	TABLET;ORAL
		400MG	TABLET;ORAL
		200MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ESLICARBAZEPINE ACETATE

Mechanism of Action	Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Anatomical Therapeutic Chemical (ATC) Classes for ESLICARBAZEPINE ACETATE

N03AF	Carboxamide derivatives
N03A	ANTIEPILEPTICS
N03	ANTIEPILEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for ESLICARBAZEPINE ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
APTIOM	Tablets	eslicarbazepine acetate	200 mg, 400 mg, 600 mg and 800 mg	022416	7	2017-11-08

US Patents and Regulatory Information for ESLICARBAZEPINE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd V	ESLICARBAZEPINE ACETATE	eslicarbazepine acetate	TABLET;ORAL	211186-001	Aug 3, 2023	AB	RX	No	No
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013	AB	RX	Yes	No	10,912,781		Y
Sph Zhongxi Pharm	ESLICARBAZEPINE ACETATE	eslicarbazepine acetate	TABLET;ORAL	211247-002	Nov 3, 2025	AB	RX	No	No

Expired US Patents for ESLICARBAZEPINE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013	5,753,646
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-002	Nov 8, 2013	10,695,354
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013	11,364,247

EU/EMA Drug Approvals for ESLICARBAZEPINE ACETATE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
BIAL - Portela & Ca, S.A.	Zebinix	eslicarbazepine acetate	EMEA/H/C/000988Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.	Authorised	no	no	no	2009-04-21
BIAL - Portela Ca, S.A.	Exalief	eslicarbazepine acetate	EMEA/H/C/000987Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.	Withdrawn	no	no	no	2009-04-21

International Patents for ESLICARBAZEPINE ACETATE

Country	Patent Number	Title	Estimated Expiration
Japan	2017014233
South Korea	20080036212	ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE
Japan	2014237658

Supplementary Protection Certificates for ESLICARBAZEPINE ACETATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0751129	C300406	Netherlands		PRODUCT NAME: ESLICARBAZEPINE, DESGEWENST IN; REGISTRATION NO/DATE: EU/1/09/514/001-020 20090421
1915346	C01915346/01	Switzerland		PRODUCT NAME: ESLICARBAZEPINACETAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67375 02.04.2020
2214636	C02214636/01	Switzerland		PRODUCT NAME: ESLICARBAZEPINACETAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67375 02.04.2020

Eslicarbazepine Acetate: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Overview

Eslicarbazepine acetate (ESL), marketed as Aptiom in the U.S. and Zebinix in Europe, is a voltage-gated sodium channel blocker used for adjunctive treatment of partial-onset seizures in adults. Its market performance is influenced by patent expiration, generic competition, and the ongoing demand for epilepsy treatments. The drug's financial trajectory is directly linked to its market penetration, pricing strategies, and the development of new indications or formulations.

Key Market Dynamics

Patent Landscape and Generic Entry

The primary patent for eslicarbazepine acetate's core compound expired in major markets, triggering generic competition.

• U.S. Patent Expiration: Key patents protecting ESL, including those related to the compound itself and its method of use, began expiring in the early 2020s. For example, U.S. Patent 7,687,500, covering crystalline forms of eslicarbazepine, expired in early 2021 [1].
• European Patent Expiration: Similar patent expiries occurred across European Union member states, allowing for generic market entry.
• Generic Approvals: The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved multiple generic versions of ESL. These approvals accelerate market access for competitors and place downward pressure on pricing [2].
• Impact on Brand Sales: Brand-name sales of Aptiom/Zebinix have experienced a decline as generic alternatives gain market share. This is a common pattern for branded pharmaceuticals post-patent expiry.

Therapeutic Landscape and Competition

ESL competes within the broader antiepileptic drug (AED) market, facing established and emerging treatments.

• Primary Indication: ESL's primary approved indication is the adjunctive treatment of partial-onset seizures in adults. This is a well-established therapeutic area with a range of existing treatment options.
• Key Competitors: ESL competes with other AEDs, including:
  • Carbamazepine and oxcarbazepine (structurally related).
  • Lamotrigine.
  • Levetiracetam.
  • Lacosamide.
  • Newer generation AEDs with novel mechanisms of action.
• Market Share Erosion: The availability of generics for established AEDs, alongside the introduction of novel therapies, contributes to market share erosion for older or second-generation drugs like ESL.
• Potential for New Indications: Future market dynamics could be influenced by the development and approval of ESL for new indications or in different patient populations. However, significant R&D investment is required for such expansions.

Pricing and Reimbursement

Pricing and reimbursement policies significantly impact ESL's financial performance.

• Brand Pricing: Prior to generic entry, branded ESL (Aptiom/Zebinix) commanded premium pricing.
• Generic Pricing: Generic versions are typically priced substantially lower, often at a discount of 70-90% compared to the branded product, to gain market access and volume [3].
• Reimbursement Policies: Payer formularies and reimbursement policies in the U.S. and Europe influence physician prescribing patterns. The preference often shifts towards generics upon their availability due to cost savings.
• Market Access Challenges: New entrants (generic ESL manufacturers) may face challenges in securing broad market access and preferred formulary status, especially in the initial phases post-approval.

Financial Trajectory and Projections

The financial trajectory of eslicarbazepine acetate is characterized by a declining branded revenue stream offset by the revenue generated by generic manufacturers.

Branded Product Performance (Aptiom/Zebinix)

The U.S. market for Aptiom, previously marketed by Supernus Pharmaceuticals, has seen its revenue peak and subsequently decline.

• Peak Sales: Supernus Pharmaceuticals reported peak net sales for Aptiom, but precise figures are subject to company disclosures and market conditions. Annual net sales in the U.S. for Aptiom reached hundreds of millions of dollars during its patent-protected period [4].
• Post-Patent Expiry Decline: Following patent expirations and the entry of generic competitors, U.S. net sales for Aptiom have significantly decreased. Supernus Pharmaceuticals has shifted focus to newer products in its pipeline.
• European Performance: Zebinix, marketed by BIAL, also experienced its revenue trajectory influenced by patent expiries and generic competition in European markets. BIAL's financial reports would provide specific data for this region.

Generic Market Performance

The financial impact of ESL is now largely driven by the success of generic manufacturers.

• Revenue Diversification: Multiple generic companies are now manufacturing and selling ESL, creating a fragmented but growing generic market.
• Volume-Driven Revenue: Generic revenue is primarily driven by sales volume rather than high per-unit pricing.
• Market Penetration: The rate at which generic ESL penetrates the market is influenced by the number of approved generic versions, their manufacturing capacity, and their marketing efforts.
• Projected Market Size: While precise future market size for generic ESL is difficult to quantify without detailed market research reports, the overall market for adjunctive treatments for partial-onset seizures remains substantial, indicating continued demand for cost-effective generic options.

Investment and R&D Outlook

Investment in ESL itself is largely complete for the branded product. The focus has shifted.

• Branded R&D: Supernus Pharmaceuticals and BIAL have completed their primary R&D investments for ESL, focusing on regulatory approvals and market launch. Further R&D would likely be directed towards new drug candidates.
• Generic R&D: Generic manufacturers' R&D efforts are focused on efficient manufacturing processes, quality control, and obtaining regulatory approvals to enter the market.
• Investment Opportunities: Investment opportunities related to ESL now primarily lie with generic pharmaceutical manufacturers or companies involved in the supply chain for generic drug production.

Competitive Analysis

Pharmaceutical Company	Product Name	Market Status	Key Dates
Supernus Pharmaceuticals	Aptiom (U.S.)	Branded product; significant generic competition	U.S. launch: 2013; Key patent expiries: Early 2020s
BIAL (Portugal)	Zebinix (EU)	Branded product; significant generic competition	EU launch: 2011; Key patent expiries: Early 2020s
Multiple Generic Manufacturers	Eslicarbazepine Acetate Generic	Generic versions available in U.S. and EU	Approvals and launches occurring post-2020s

Key Takeaways

Eslicarbazepine acetate has transitioned from a branded pharmaceutical product with significant revenue potential to a market characterized by robust generic competition. The financial trajectory of the branded product has shifted from growth to decline, while the generic market for ESL is expanding. Future revenue generation for ESL is predominantly linked to the volume and market penetration achieved by generic manufacturers.

Frequently Asked Questions

1. What is the primary therapeutic use of eslicarbazepine acetate? Eslicarbazepine acetate is used for the adjunctive treatment of partial-onset seizures in adults.
2. When did key patents for eslicarbazepine acetate begin to expire? Key patents for eslicarbazepine acetate began expiring in the early 2020s in major markets like the U.S. and Europe.
3. Who were the primary developers and marketers of the branded eslicarbazepine acetate? Supernus Pharmaceuticals developed and marketed Aptiom in the U.S., while BIAL developed and marketed Zebinix in Europe.
4. What is the typical impact of generic entry on the pricing of a pharmaceutical drug? Generic entry generally leads to a significant decrease in the price of the drug, often by 70-90%, as lower-cost alternatives become available.
5. Where do current investment opportunities lie regarding eslicarbazepine acetate? Investment opportunities related to eslicarbazepine acetate now primarily exist with generic pharmaceutical manufacturers and companies involved in the generic drug supply chain.

---

Citations

[1] U.S. Patent 7,687,500. (2010). Crystalline forms of eslicarbazepine. Google Patents. [2] U.S. Food and Drug Administration. (n.d.). Orange Book. Retrieved from [FDA website] (Specific URL for generic approvals may vary based on search query and date). [3] Generic Pharmaceutical Association. (2020). The Value of Generic and Biosimilar Medicines. [4] Supernus Pharmaceuticals, Inc. (2022). Annual Report on Form 10-K for the fiscal year ended December 31, 2021. U.S. Securities and Exchange Commission.